2026-06-15
Calian Group is an Ottawa-based diversified services company delivering mission-critical solutions across four segments: Advanced Technologies (satellite, RF, and defence systems), Health (clinical staffing, digital health), Learning (simulation-based military and corporate training), and IT and Cyber Solutions (managed services, cybersecurity). Founded in 1982 and publicly traded since 1993, Calian has achieved eight consecutive years of double-digit revenue growth, targeting CAD $1 billion in revenue by fiscal 2026. Its government and defence client base provides sticky, recurring revenue. The company grows through both organic initiatives and strategic bolt-on acquisitions funded from strong free cash flow.
Intrinsic Value Calculations
Key Financial Inputs Used
| Input | Value |
|---|---|
| Revenue FY2024 | CAD $746.6M |
| Revenue FY2025 | CAD $774.1M |
| Revenue TTM | CAD ~$832M |
| Operating Income FY2024 | CAD $46.0M |
| Adjusted EBITDA FY2024 | ~CAD $86M |
| Net Income FY2025 | CAD $20.6M |
| EPS (reported, TTM) | CAD ~$0.94–$1.03 |
| EPS (adjusted / normalized est.) | CAD ~$4.00 |
| Free Cash Flow FY2024 | CAD $48.7M |
| FCF per share | CAD $4.29 |
| Shares Outstanding | ~11.35M |
| Total Debt (Long-term, Q1 FY26) | CAD $164.8M |
| Cash | CAD $62.6M |
| Net Debt | CAD ~$102M |
| Total Assets | CAD $750.5M |
| Goodwill + Intangibles | CAD ~$337M |
| Tangible Book Value | ~CAD $55M est. |
| Revenue CAGR (13-year historical) | 10% |
| Revenue CAGR (3-year forward est.) | 8% |
| Net Income growth (3-yr projected) | 48% p.a. (from a low base) |
| EV/EBITDA | 9.53x |
| EV/FCF | 13.64x |
| Beta | 0.51–0.82 |
| Current Ratio | 1.41 |
| Debt/Equity | 0.61 |
| ROE | ~3% (reported); improving |
| ROIC | ~3.3–4.4% |
| Altman Z-Score | 2.21 |
| Piotroski F-Score | 5 / 9 |
| Annual Dividend | CAD $1.12 |
| Dividend Yield | ~1.35% |
Valuation Results
| Method | Inputs Used | Intrinsic Value (CAD) | Signal vs. $83 |
|---|---|---|---|
| DCF (Conservative) | FCF $48.7M; 5-yr growth 8%; terminal 3%; discount rate 10% | $65–$72 | OVERVALUED ~15–22% |
| DCF (Base Case) | FCF $48.7M; 5-yr growth 10%; terminal 3.5%; discount 9% | $82–$90 | FAIRLY VALUED |
| DCF (Bull Case) | FCF growing to $65M by yr3; 12% growth; 9% discount | $105–$118 | UNDERVALUED ~26–42% |
| MEV / EV/EBITDA | Adj. EBITDA ~$90M; sector median 10–12x EV/EBITDA | $78–$98 | NEAR FAIR VALUE |
| FCF Yield Multiple | FCF/share $4.29; 15–18x FCF fair for growing govt services co. | $64–$77 | SLIGHTLY OVERVALUED |
| Earnings Power Value | Normalized EPS ~$4.00; sector P/E 18–22x | $72–$88 | FAIRLY VALUED |
| Blended / Central Estimate | Average across all methods | ~$80–$88 | NEAR FAIR / SLIGHT DISCOUNT |
PE, PEG, PEGY
| Metric | Value | Interpretation |
|---|---|---|
| PE (reported, TTM) | ~88x (using GAAP EPS ~$0.94) | Distorted by non-cash amortization of acquired intangibles |
| PE (normalized/adj. EPS ~$4.00) | ~20.8x | Reasonable for a growing govt services compounder |
| PEG (adjusted) | ~0.87x (using 7.2% fwd EPS growth on adj. basis) | Below 1.0 = potentially undervalued on growth-adjusted basis |
| PEGY | ~0.80x (PEG minus dividend yield of 1.35%) | Below 1.0 = favourable; Dividend adds meaningful return cushion |
Investment Questions
| Question | Answer / Assessment |
|---|---|
| Is the business model simple and sustainable? | YES Four segments (Tech, Health, Learning, IT/Cyber) serving government, defense, healthcare. Long-term contracts provide visibility. Model is service-heavy, capital-light. |
| Intrinsic values, PE, PEG, PEGY | DCF base: $82–$90; MEV: $78–$98; Blended: ~$84. Norm. PE ~20.8x, PEG ~0.87, PEGY ~0.80. Fairly to modestly undervalued. |
| Durable competitive advantage (moat)? | MODERATE High switching costs (government certifications, clearances, entrenched IT systems). Moat is narrow but deepening via M&A. Not a wide-moat business. |
| Competitors and positioning | Competes with Maximus, Leidos, MDA Space, Paladin Labs, CGI Group. Calian occupies a differentiated niche: smaller, faster, more flexible than defence primes. Positioned well in Canadian defence. |
| Management quality | STRONG Kevin Ford (until Q1 FY26) then Patrick Houston elevated to CEO. Eight consecutive record revenue years. NCIB buybacks. Low insider ownership (1.2%) is a mild concern. |
| Is the stock undervalued vs. intrinsic value? | BORDERLINE At $83, roughly fairly valued on base DCF. Bull case (EBITDA expansion + margin improvement) supports ~20–40% upside. Not a deep-value purchase; a quality-at-fair-value opportunity. |
| Capital efficiency? | IMPROVING ROIC ~3.3–4.4% is below cost of capital today, but improving as acquired businesses integrate. Watch FY2026 as restructuring benefits flow through. |
| Free cash flow strength? | SOLID FCF ~$48.7M in FY2024; 68% conversion from adj. EBITDA. FCF per share $4.29. Capex light ($9.8M). Funds M&A and dividends comfortably. |
| Balance sheet strength? | ADEQUATE Net debt ~$102M; ND/EBITDA ~1.2x – manageable. Goodwill/intangibles $337M is ~47% of total assets – elevated but typical of acquisition-led model. Current ratio 1.41x. |
| Earnings and revenue consistency? | STRONG 8 consecutive years of double-digit revenue growth. Revenue CAGR 10% over 13 years. GAAP earnings volatile due to acquisition amortization; adjusted EBITDA and FCF are stable and growing. |
| Margin of safety? | MODEST ~5–10% below base DCF. Margin of safety is thin at $83. Meaningful safety (25%+) requires entry at $60–$65. |
| Biggest risks? | Government budget cuts; acquisition integration failure; low ROIC; GAAP earnings optics; intangible impairment risk; low insider ownership; FX (international contracts). |
| Shareholder dilution? | DISCIPLINED Share count actually decreased 2.4% YoY via NCIB. Acquisitions are bolt-on and funded with a mix of cash/credit. No egregious dilution. |
| Cyclical or stable? | STABLE / DEFENSIVE Government contracts are recession-resistant. Defence spending tends to increase in recessions or geopolitical stress. Revenue is highly recurring. |
| 5–10 year outlook? | If management executes on defence/space tailwinds and EBITDA margins expand to 13–15%, the company could be a CAD $1.2–1.5B revenue compounder with $7–9 EPS by 2033–2035. |
| Would you hold if the market closed 5 years? | YES – with moderate conviction. Revenue visibility is high; dividend is paid; the defence/space/healthcare secular trends are durable. |
| PEGY and what it indicates? | PEGY ~0.80. Below 1.0 suggests the stock is attractive relative to its growth rate and dividend. Peter Lynch considered sub-1.0 PEGY a buy signal. Calian qualifies on this metric. |
| Capital reinvestment vs. shareholder returns? | Balanced: M&A drives growth; dividends ($1.12/share) provide income; NCIB reduces share count. Reinvestment quality improving. Capital allocation has been disciplined. |
| Why is the stock potentially mispriced? | GAAP EPS appears low ($0.94 TTM) due to large acquisition amortization charges ($30–40M/yr). The market may be penalizing on GAAP optically. FCF and adj. EBITDA tell a better story. |
| Thesis assumptions and what invalidates them? | Assumes: defence spending holds; margin expansion occurs; M&A integration succeeds; FCF continues growing. Invalidated by: government austerity; integration failures; ROIC remaining below 5%; macro downturn. |
| Portfolio fit? | Suitable as a defensive-growth holding (5–10% portfolio weight) alongside cyclical and technology positions. Adds Canadian small-cap defence exposure with dividend income. |
| Buy / Hold / Sell at $83? | HOLD / ACCUMULATE ON WEAKNESS Intrinsic value ~$82–$90 base case. At $83, risk/reward is balanced but not compelling. Ideal entry: $65–$72 for 25%+ margin of safety and 9%+ CAGR path. Target buy price for 9%/yr over 16 yrs: $63–$67. |
Intrinsic Value: Methods and Assumptions
A. Discounted Cash Flow (DCF)
Starting FCF of CAD $48.7M (FY2024 actuals: $58.45M operating CF minus $9.77M capex). Three scenarios modelled over 10 years with the following key assumptions:
| Scenario | FCF Growth Yr 1–5 | FCF Growth Yr 6–10 | Terminal Growth | Discount Rate | Equity Value / Share |
|---|---|---|---|---|---|
| Bear | 5% | 3% | 2.5% | 10.5% | ~$52–$58 |
| Base | 10% | 6% | 3.5% | 9.0% | ~$82–$90 |
| Bull | 14% | 8% | 4% | 8.5% | ~$115–$125 |
Net debt of ~$102M is subtracted from enterprise value. Shares outstanding: 11.35M. The discount rate is set above the risk-free rate to reflect the small-cap premium and integration risk.
B. Market / EV Multiple Valuation (MEV)
Using adj. EBITDA of ~$90M (FY2025 est.) and applying comparable company multiples:
| EV/EBITDA Multiple | Enterprise Value | Equity Value | Per Share (11.35M) |
|---|---|---|---|
| 8x (Bear) | $720M | $618M | $54 |
| 10x (Base) | $900M | $798M | $70 |
| 12x (Bull) | $1,080M | $978M | $86 |
| 14x (Premium) | $1,260M | $1,158M | $102 |
The current stock price of $83 implies ~10.3x adj. EBITDA – roughly in line with peers, suggesting the market is pricing Calian fairly on this metric.
Detailed Analysis
Business Understanding
Calian operates across four service segments. Advanced Technologies delivers satellite ground systems, RF and antenna solutions, GNSS products, and military communications hardware – revenues here are tied to NATO defence contracts, space agencies, and international telecommunications operators. Health provides clinical staffing, occupational health, and digital health platforms to federal and provincial governments and to large employers – a business that benefits from chronic shortages of healthcare workers and the trend toward outsourced government health services. Learning delivers simulation-based military training, e-learning platforms, and immersive corporate learning programs – increasingly valuable as defence forces modernise and as digital-first training becomes standard. IT and Cyber Solutions (ITCS), the most recent acquisition-heavy segment, delivers managed IT services, cybersecurity monitoring, and cloud solutions, primarily to Canadian federal clients.
The business model is services-led, labour-intensive, and relatively capital-light, generating strong FCF. Demand is structurally stable – governments do not stop needing healthcare, defence training, or IT infrastructure. The primary demand risk is not economic cyclicality but political: a change in procurement priorities or a freeze on defence spending could slow contract renewals. However, the secular trend (Canada’s NATO commitment to 2% of GDP) is strongly in Calian’s favour for the next decade.
Competitive Advantage (Moat)
Calian’s moat is narrow but real. It operates in markets with high switching costs: once embedded in a government IT environment or military training programme, replacement is costly, politically inconvenient, and technically risky. Security clearances are an additional barrier – Calian’s staff hold classified-level clearances that take years to obtain, creating a meaningful talent and contract lock-in. The company is not a commodity supplier; it provides specialised expertise that is difficult to replicate quickly.
The moat is not pricing power-driven in the traditional sense – government contracts often cap margins – but it is durability-driven: long-term contracts (multi-year, often 3–7 years), recurring revenue, and entrenched client relationships. The moat is narrower than that of a Lockheed Martin or L3Harris but wider than a pure staffing agency. The risk of moat erosion comes from larger primes entering the niche Canadian market or from disruptive technologies (AI-based training platforms, autonomous health diagnostics) displacing Calian’s labour-centric model.
Financial Strength: Profitability
Revenue has grown at a 10% CAGR over 13 years – a genuinely impressive track record for a CAD $750M company. Adjusted EBITDA margins have improved from ~9% in FY2020 to ~11.5% in FY2024 and appear to be accelerating (Q1 FY26 EBITDA up 28% on 12% revenue growth, implying margin expansion to ~13–14%). GAAP net income is distorted by large non-cash amortisation charges on acquired intangibles (~$40–50M annually), which artificially suppresses reported EPS and P/E. The FCF story is healthier: $4.29/share in FCF against a stock price of $83 implies a 5.2% FCF yield, which is respectable for a growing business.
Financial Strength: Balance Sheet
Net debt of ~$102M against adj. EBITDA of ~$90M equates to a ND/EBITDA ratio of 1.1–1.2x – well within the comfort zone for an acquisition-led model. The current ratio of 1.41x suggests adequate short-term liquidity. The key concern is the goodwill and intangibles balance of ~$337M (47% of total assets), which reflects the cumulative acquisition price paid above book value. The Altman Z-Score of 2.21 places Calian in the “grey zone” (1.81–2.99), not distress territory but meriting monitoring. Goodwill impairment risk is real if the ITCS segment (which carries the largest intangibles allocation at $182M) underperforms.
Margin of Safety
At $83, the margin of safety against base-case intrinsic value of $82–$90 is minimal – approximately 0–10%. For a disciplined value investor requiring a 25% margin of safety, the appropriate entry price is $62–$67. The bull case ($115–$125 IV) provides a significant 28–42% discount, but achieving it requires EBITDA margin expansion to 14–15% and continued acquisition success – assumptions that may not be warranted without additional evidence.
The investor must make a judgment: is Calian a “pay fair price for a great business” opportunity (a la Munger) or does the limited margin of safety make it a pass? Given the 8% revenue growth forecast, PEGY below 1.0, and genuine defence tailwinds, it sits closer to the former – but only modestly. Patience to wait for a $65–$70 entry is rewarded with a much more favourable risk/reward.
Weighted SWOT Analysis
| Factor | Weight | Score (1–10) | Weighted | Detail |
|---|---|---|---|---|
| STRENGTHS | ||||
| 8 years double-digit revenue growth | 15% | 9 | 1.35 | Rare consistency in services sector; revenue CAGR 10% over 13 years |
| Diversified, recession-resistant segments | 12% | 8 | 0.96 | Defence, healthcare, government spending holds through downturns |
| Strong FCF generation ($48.7M; 68% conversion) | 10% | 8 | 0.80 | Funds M&A, dividends, and buybacks without external dilution |
| Dividend + NCIB shareholder returns | 8% | 7 | 0.56 | $1.12/share dividend; share count declining |
| Defence/space tailwinds (NATO 2% GDP commitments) | 10% | 9 | 0.90 | Canada’s defence spending increasing; CGY well-positioned |
| WEAKNESSES | ||||
| Low ROIC (3.3–4.4%); below cost of capital | 12% | 3 | 0.36 | Acquisitions have not yet generated adequate returns |
| High goodwill/intangibles ($337M, ~47% assets) | 8% | 3 | 0.24 | Impairment risk if acquired businesses underperform |
| Low insider ownership (1.2%) | 5% | 3 | 0.15 | Management skin-in-the-game is limited |
| GAAP earnings opaque (amortization distorts) | 5% | 4 | 0.20 | Market may misread earnings; analysts must adjust |
| OPPORTUNITIES | ||||
| Path to $1B+ revenue by FY2026; margin expansion | 8% | 8 | 0.64 | Q1 FY26 already shows 12% revenue growth; EBITDA up 28% |
| International expansion in defence/space | 4% | 7 | 0.28 | Hawaii Pacific Teleport; global satellite operations |
| THREATS | ||||
| Government budget cuts / procurement delays | 2% | 5 | 0.10 | Single largest risk; especially in Canadian fiscal tightening scenario |
| Integration failure risk (serial acquirer) | 1% | 4 | 0.04 | 3 acquisitions in FY2024 alone increases complexity |
| TOTAL WEIGHTED SCORE | 6.58 / 10 | Above average; modest conviction buy on weakness | ||
Bear, Base, and Bull Scenarios
| Scenario | Revenue Assumption | EBITDA Margin | FCF / Share | Intrinsic Value | Return from $83 |
|---|---|---|---|---|---|
| Bear Case (20% prob.) | Flat $750M; gov’t cuts, one failed acquisition | 9% | $3.00 | $52–$62 | -25% to -37% |
| Base Case (55% prob.) | 8–10% CAGR to ~$1.05B by FY2027 | 12–13% | $5.50–$6.50 | $82–$95 | -1% to +14% |
| Bull Case (25% prob.) | 12–14% CAGR; margin expansion to 15%; M&A accretive | 14–16% | $8.00+ | $115–$130 | +39% to +57% |
Bear case assumes one or two material acquisition impairments, reduced DND (National Defence) contract flow, and sustained low ROIC. Dividend likely maintained but growth stalls.
Base case reflects current trajectory: disciplined M&A, growing defence spending, EBITDA margin expansion driven by cost optimisation launched in late FY2025. Revenue reaches $1B+ by FY2027. Shareholders earn 7–10% annually.
Bull case assumes Calian successfully integrates all acquisitions, margin expands toward 15%, defence spending accelerates under NATO pressure on Canada, and the stock re-rates to a premium services multiple (14–16x EBITDA). 5-year return could exceed 60%.
Entry trigger: Buy below $67 for a margin of safety aligned with 9% CAGR requirement. Consider adding aggressively if the stock falls below $55 (bear-scenario entry with 30% margin of safety).
Exit trigger: Begin trimming above $105; consider full exit above $125 unless a new bull case thesis justifies higher multiple.
Buy Price for Various Return Targets (16-Year Horizon)
Uses base case intrinsic value of $88 as the 16-year target (conservative). A more aggressive bull scenario target of $115 is also shown. Present value discounted at the required return rate.
| Target Annual Return | Buy Price (Base $88 target) | Buy Price (Bull $115 target) |
|---|---|---|
| 5% / year over 16 years | $40.84 | $53.34 |
| 6% / year over 16 years | $34.69 | $45.29 |
| 7% / year over 16 years | $29.49 | $38.51 |
| 8% / year over 16 years | $25.15 | $32.83 |
| 9% / year over 16 years | $21.51 | $28.08 |
| 10% / year over 16 years | $18.45 | $24.09 |
Note: These prices assume the intrinsic value at the end of 16 years is $88 (base) or $115 (bull). In practice, the company’s intrinsic value will itself compound over 16 years, making these buy prices highly conservative. A more realistic target in 16 years (at 8% value CAGR) is $280–$350, making the current price of $83 plausible for a 9% return under an optimistic scenario.
Buy Price for 9% Annual Return at Different Holding Periods
Assumes the stock reaches intrinsic value of $88 (base) by the target year. Price today to earn 9% annualised.
| Holding Period | Required Buy Price (9%/yr; $88 target) | Dividend Contribution (est.) |
|---|---|---|
| 5 years | $57.16 | Adds ~0.8–1.2% effective yield |
| 7 years | $48.12 | Growing dividend improves IRR |
| 10 years | $37.18 | Dividends material at longer horizons |
| 12 years | $31.22 | ~$13.44 cumulative dividends at $1.12/yr |
| 14 years | $26.25 | ~$15.68 cumulative dividends |
| 16 years | $22.07 | ~$17.92 cumulative dividends |
These buy prices are based on a static $88 terminal value. If Calian’s intrinsic value itself compounds at 8% per year (plausible given growth trajectory), the 16-year terminal value would be ~$290, making the current price of $83 a credible entry for a 9%+ return over 16 years under the bull case.
When to Trim and When to Sell
| Action | Price Range (CAD) | Condition |
|---|---|---|
| Begin trimming (sell 25%) | $100–$110 | Stock approaches 20–25% above base DCF; re-evaluate thesis |
| Trim further (sell 50%) | $115–$125 | Approaches bull case IV; margin of safety fully consumed |
| Full exit (sell all) | $130+ | Exceeds bull case IV, EBITDA multiple above 14–15x, or thesis broken |
| Sell on thesis break | Any price | ROIC stays below 4% for 3 years; major acquisition impairment; government contract concentration rises above 60%; management integrity concerns |
Risk Score
| Component | Weight | Score (1=Low Risk, 10=High Risk) | Weighted Score | Rationale |
|---|---|---|---|---|
| Financial Stability | 30% | 4.5 | 1.35 | ND/EBITDA 1.2x manageable; Altman Z 2.21 (grey zone); current ratio 1.41x adequate |
| Earnings Volatility | 20% | 5.0 | 1.00 | GAAP earnings highly volatile; adj. EBITDA and FCF stable – scoring reflects optically volatile GAAP |
| Business Model Risk | 20% | 3.5 | 0.70 | Government/defence clients provide recurring revenue; multiple segments reduce concentration |
| Macro Sensitivity | 15% | 3.0 | 0.45 | Defence and health spending are counter-cyclical; limited cyclical exposure |
| Market Risk | 15% | 4.0 | 0.60 | Beta 0.51–0.82; small-cap illiquidity premium; TSX-listed micro-cap by global standards |
| Total Risk Score | 100% | 4.10 / 10 | BELOW AVERAGE RISK |
A score of 4.1/10 implies below-average risk for this class of investment. The primary risks are operational (acquisition integration, ROIC recovery) rather than existential. The defensive nature of government contracts is the key risk mitigant.
Opportunity Score
| Component | Weight | Score (1=Poor, 10=Excellent) | Weighted Score | Rationale |
|---|---|---|---|---|
| Growth Potential | 30% | 7.5 | 2.25 | 8% revenue CAGR forecast; 12% Q1 FY26 actual; margin expansion underway; defence tailwinds |
| Unit Economics | 20% | 6.0 | 1.20 | FCF conversion strong (68%); EBITDA margins improving; ROIC still below COC – partial score |
| Competitive Advantage | 20% | 6.5 | 1.30 | Switching costs, govt clearances, entrenched position – narrow but real moat |
| Valuation Asymmetry | 20% | 6.0 | 1.20 | PEGY 0.80; EV/EBITDA 9.5x is reasonable; not deeply cheap but not expensive |
| Catalysts | 10% | 7.5 | 0.75 | NATO defence spending surge; Canada $1B revenue milestone; EBITDA margin expansion announcement |
| Total Opportunity Score | 100% | 6.70 / 10 | ABOVE AVERAGE OPPORTUNITY |
An opportunity score of 6.7/10 indicates a materially attractive setup – above average upside driven by structural tailwinds and operating leverage, constrained only by the modest margin of safety at current prices and the ROIC recovery story yet to fully unfold.
Red Flag Scan
| Red Flag Category | Present? | Assessment |
|---|---|---|
| Declining free cash flow | NO | FCF growing; $48.7M in FY2024, up from prior years |
| Rising debt without rising earnings | WATCH | Debt rising ($164M LTD) but adj. EBITDA rising commensurately. ND/EBITDA stable at 1.2x. |
| Management compensation misaligned | MILD CONCERN | Low insider ownership (1.2%). Options/RSU structure not fully public. Worth monitoring proxy. |
| Serial acquisitions (diworsification risk) | PRESENT | 3 acquisitions in FY2024; 2 more in FY2025. So far disciplined (bolt-ons in core verticals). Watch for unrelated diversification. |
| Accounting complexity | MILD | GAAP earnings obscured by amortization; non-GAAP metrics necessary. Not fraudulent, but requires investor adjustment. |
| Moat erosion | NOT CURRENTLY | Moat is narrow but stable. AI in training/health is a longer-term watch item. |
| Overreliance on one customer/product | LOW | No single customer disclosed as >10%. Four segments reduce concentration. Canadian DND is likely largest client but not disclosed at alarming levels. |
| ROIC below cost of capital | YES | Most significant red flag. ROIC ~3.3–4.4% vs. est. WACC of ~8–9%. Acquisitions must generate higher returns or capital destruction results. |
| Goodwill bloat | ELEVATED | $337M intangibles / $750M assets = 47%. Impairment test annual; ITCS segment highest risk. |
Classification and Investor Archetypes
| Framework | Classification | Reasoning |
|---|---|---|
| Business Stage | GROWING | 8 consecutive years of double-digit revenue growth; targeting $1B+ in FY2026; new segments expanding. Not cyclical or declining. |
| Peter Lynch Classification | Fast Grower / Stalwart Hybrid | Lynch would categorize Calian as a “Fast Grower” graduating into a “Stalwart.” Revenue growing 8–12% annually, dividend paid, recession-resistant. Lynch loved government-dependent businesses with consistent revenue. The PEGY below 1.0 would attract Lynch immediately. He would note the serial acquisition strategy as a mild concern (watch for “diworsification”) but would be reassured by the focused vertical approach (defence, health, learning, cyber). |
| Charlie Munger Classification | Good Business at Fair Price | Munger would appreciate the long-term government contracts (predictable cash flows), diversified service mix, and recurring revenues. He would focus on whether the moat is genuinely widening and whether management is deploying capital rationally. He would be cautious about the low ROIC (below cost of capital) and the serial acquisition model. However, the improving EBITDA margins and management discipline on NCIB would appeal to him. His verdict: “A good business at a fair price – worth holding, not worth rushing into.” Munger would want to see ROIC above 10% before calling it a great business. |
Data Used and Data Excluded
| Data Used | Data Excluded / Why |
|---|---|
| Revenue FY2022–FY2025 and TTM (growth trend analysis) | Quarterly EPS estimates (too granular for LT thesis) |
| Adjusted EBITDA, FCF, and FCF/share | GAAP net income as primary valuation driver (distorted by amortization) |
| EV/EBITDA, EV/FCF ratios | Price/Book (intangibles-heavy; tangible book is minimal) |
| Debt/Equity, ND/EBITDA, current ratio | Quarterly segment-level margins (insufficient public data) |
| Altman Z-Score, Piotroski F-Score | Short-term technical indicators (RSI, moving averages) – not relevant for LT value investor |
| Beta (risk calibration), dividend yield | Exact pension liabilities (not prominently disclosed) |
| Goodwill + intangibles as % of total assets | Employee stock options outstanding (limited disclosure) |
| Analyst consensus price targets ($90.9–$105) | Short interest data |
| Management commentary on EBITDA expansion and FY2026 guidance | Day-to-day news flow and macro forecasts |
| Historical CAGR (10% over 13 years) and forward 3-yr est. (8%) | FX impact (limited; ~90%+ revenue is CAD-denominated) |
Summary and Final Verdict
Final Verdict: HOLD / ACCUMULATE ON WEAKNESS
Calian Group is a rare Canadian small-cap compounder: eight consecutive years of double-digit revenue growth, strong free cash flow conversion, recession-resistant government and defence revenues, and an increasingly favourable macro backdrop as NATO allies – including Canada – accelerate defence spending. The business is not cheap at $83 (fairly valued at $82–$90 base case), but it is a quality franchise at a reasonable price.
The primary risks are the low ROIC (currently 3–4%, below cost of capital), the elevated goodwill from serial acquisitions, and GAAP earnings that confuse rather than inform. The primary opportunity is operating leverage: as recently restructured operations flow through in FY2026, adjusted EBITDA margins are expanding (Q1 FY26: EBITDA up 28% on 12% revenue growth), suggesting significant earnings power not yet fully reflected in price.
For a 9% annual return over 16 years: Based on a conservative terminal intrinsic value of $88 (base case), the required entry price is approximately $21–$28 – clearly below the current price. However, if Calian’s own intrinsic value compounds at 8% annually over 16 years (a reasonable assumption given its track record), the 16-year intrinsic value would approach $280–$350, making today’s price of $83 a plausible entry point for a 9%+ compounding scenario under the bull case. The key is patience and the compounding of Calian’s own intrinsic value, not just price.
Ideal entry: $65–$72. Add aggressively below $60. Begin trimming above $105.
Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Always perform your own due diligence or consult with a financial advisor before making investment decisions.
